Form 4: Ionis Pharmaceuticals Executive Receives Stock Options
SEC Form 4
Joseph Baroldi, EVP and Chief Business Officer at Ionis Pharmaceuticals, was granted stock options, with a portion also granted to his spouse.
Summary
- Joseph Baroldi, an executive at Ionis Pharmaceuticals, received 22,000 non-qualified stock options on January 2, 2025, at an exercise price of $34.69.
- His spouse also received 2,500 non-qualified stock options on the same date, with the same exercise price.
- The options were granted under the company's 2011 Equity Incentive Plan.
- The options vest over time, with 25% becoming exercisable on January 2, 2026, and the remainder vesting in 36 equal monthly installments over the following three years.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The stock options will vest over the next three years, incentivizing the executive's performance and long-term commitment to the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry, similar to companies like Biogen, Gilead Sciences, and Amgen.
- The vesting schedule of 25% after one year and the remainder over three years is also typical for these types of grants.
Stakeholder Impact
- Shareholders may view the stock option grants positively as they incentivize management to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of stock option grants to Joseph Baroldi and his spouse. |
| 01/02/2026 | Date when 25% of the granted stock options become exercisable. |
| 01/01/2035 | Expiration date of the stock options. |
| 01/03/2025 | Date the form was signed by attorney-in-fact. |
Keywords
stock options, equity incentive plan, executive compensation, vesting, Ionis Pharmaceuticals, Joseph Baroldi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.